Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva

NEW YORK, June 26, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Forest Laboratories Inc. (NYSE: FRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD) and Gentiva Health Services Inc. (NASDAQ: GTIV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4129-100free.

--
Actavis plc Analyst Notes
On June 23, 2014, Actavis plc (Actavis) together with Forest Laboratories Inc. (Forest) announced that C. David Nicholson, PhD has been appointed as Senior Vice President, Actavis Global Brands R&D following the close of Actavis' planned acquisition of Forest, effective August 4, 2014. In this new position, Dr. Nicholson will lead the global teams focused on developing Actavis' significantly expanded branded R&D portfolio, as well as defining long-term product development strategies and collaborations. "David is a seasoned R&D leader who has transformed organizations into drug development powerhouses," said Brent Saunders, CEO and President at Forest. "He brings an exceptional track record spanning more than 30 years in the industry to this critical brand product development position within the new Actavis. His expertise in the development of a diverse portfolio of products including treatments in women's health, psychiatry, cardiovascular, anesthesiology and immunology, matches exceptionally well with our current portfolio, as well as our therapeutic category focus." Dr. Nicholson is currently the Chief Technology Officer, Executive Vice President R&D of Bayer Crop Sciences. The full analyst notes on Actavis are available to download free of charge at:

http://www.analystsreview.com/Jun-26-2014/ACT/report.pdf

--
Forest Laboratories Inc. Analyst Notes
On June 17, 2014, Forest Laboratories Inc. (Forest) reported that shareholders of the Company as well as that of Actavis plc (Actavis) have approved the planned acquisition of the Company by the latter. Actavis' and Forest's shareholder approvals satisfy certain conditions to the closing of the transaction, which is expected to occur at mid-2014. The full analyst notes on Forest are available to download free of charge at:

http://www.analystsreview.com/Jun-26-2014/FRX/report.pdf

--
Vertex Pharmaceuticals Incorporated Analyst Notes
On June 18, 2014 Vertex Pharmaceuticals Inc. (Vertex) announced that it has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. (Janssen) for the worldwide development and commercialization of VX-787, one of Vertex's discoveries of a novel medicine for the treatment of influenza. Under the terms of agreement, Vertex will receive an up-front payment of $30 million from Janssen and has the potential to receive additional development and commercial milestone payments as well as royalties on future product sales. "With a deep history in developing new medicines for viral infections and diseases, Janssen is well-positioned to advance the global development of VX-787 for the treatment of influenza," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and CEO of Vertex. "This collaboration provides important support for the continued development of VX-787 in influenza and contributes to our financial strength to enable continued investment in our key development programs for cystic fibrosis and in research aimed at discovering new medicines." The full analyst notes on Vertex are available to download free of charge at:

http://www.analystsreview.com/Jun-26-2014/VRTX/report.pdf

--
MannKind Corp. Analyst Notes
On June 23, 2014, MannKind Corp.'s stock increased 3.67% to end the day at $10.73 compared to the previous day's closing price at $10.35. The Company's stock grew 1.80% over the past three trading days compared to the Nasdaq Composite which rose 0.13% during the same trading period. The full analyst notes on MannKind are available to download free of charge at:

http://www.analystsreview.com/Jun-26-2014/MNKD/report.pdf

--
Gentiva Health Services Inc. Analyst Notes
On June 16, 2014, Gentiva Health Service Inc. (Gentiva) reported that it has urged the Company's shareholders to take no step in response to tender offer announcement by Kindred Healthcare, Inc. (Kindred). According to Gentiva, Kindred intend to commence a tender offer to acquire all of the outstanding shares of Gentiva common stock for $14.50 per share in cash. The Company informed that its Board of Directors will review all aspects of the proposed offer with its financial and legal advisors and make a recommendation to Gentiva shareholders, which will be outlined in a Statement on Schedule 14D-9 to be filed with the Securities and Exchange Commission within 10 business days of commencement of the Tender Offer. The full analyst notes on Gentiva are available to download free of charge at:

http://www.analystsreview.com/Jun-26-2014/GTIV/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED